The present disclosure relates to imaging and endoradiotherapy of diseases involving chemokine receptor 4 (CXCR4). Provided are compounds which bind or inhibit CXCR4 and furthermore carry at least one moiety which is amenable to labeling. Provided are also medical uses of such compounds.

The present disclosure relates to imaging and endoradiotherapy of diseases involving chemokine receptor 4 (CXCR4). Provided are compounds which bind or inhibit CXCR4 and furthermore carry at least one moiety which is amenable to labeling. Provided are also medical uses of such compounds.

Provided are a contrast agent for optical imaging, a use thereof and an apparatus using the same. The contrast agent for optical imaging of the present disclosure allows optical imaging without requiring a fluorophore or a luminophore. As a result, the optical images can be acquired without changing the physicochemical properties of a substrate. The contrast agent for optical imaging of the present disclosure may be used as an optical/nuclear bimodal imaging contrast agent for many applications, and allows radiation therapy as well as monitoring of a therapeutic effect thereof through optical imaging at the same time. Further, when a fluorophore is attached thereto, light emission may be enhanced without energy input from outside since light is emitted from the fluorophore, thereby increasing luminescence intensity and improving tissue penetration.

Provided are a contrast agent for optical imaging, a use thereof and an apparatus using the same. The contrast agent for optical imaging of the present disclosure allows optical imaging without requiring a fluorophore or a luminophore. As a result, the optical images can be acquired without changing the physicochemical properties of a substrate. The contrast agent for optical imaging of the present disclosure may be used as an optical/nuclear bimodal imaging contrast agent for many applications, and allows radiation therapy as well as monitoring of a therapeutic effect thereof through optical imaging at the same time. Further, when a fluorophore is attached thereto, light emission may be enhanced without energy input from outside since light is emitted from the fluorophore, thereby increasing luminescence intensity and improving tissue penetration.

Multi-modal imaging capsule for image-guided proton beam therapy, consisting of a biocompatible polymer layer, .sup.18O-enriched water, and a contrast agent. The biocompatible capsule may be inserted near or inside a tumor under the guidance of X-ray, magnetic resonance, or ultrasonography imaging. Upon proton beam irradiation, the capsule emits positrons, allowing the tumor to be imaged and tracked by a PET detector.

This invention relates to strontium-phosphate microparticles that incorporate radioisotopes for radiation therapy and imaging.

This invention relates to strontium-phosphate microparticles that incorporate radioisotopes for radiation therapy and imaging.

Among the various aspects of the present disclosure is the provision of compositions of imaging agents and methods for use in detecting, monitoring, and evaluating CCR2 associated diseases, disorders, and conditions.

Among the various aspects of the present disclosure is the provision of compositions of imaging agents and methods for use in detecting, monitoring, and evaluating CCR2 associated diseases, disorders, and conditions.

Systems and methods for enhanced diagnosis of transthyretin-related cardiac amyloidosis in a subject are disclosed. The systems and methods may use both SPECT imaging data as well as an anatomical imaging data, such as computed tomography (CT) data, to produce a combined image. Within the combined image, the radiotracer uptake between two volumes of interests are compared, one of which may represent the left ventricle of the subject and the other may represent the blood pool retention of the subject. Combining the anatomical imaging data with SPECT data enables better anatomical delineation and helps in avoiding areas with coronary or lymph node calcifications and overlying soft tissue and bony pathologies.